Improved Overall Survival, Relapse-Free-Survival, and Less Graft-vs.-Host-Disease in Patients With High Immune Reconstitution of TCR Gamma Delta Cells 2 Months After Allogeneic Stem Cell Transplantation.
Adult
Aged
Female
Graft vs Host Disease
/ diagnosis
Hematopoietic Stem Cell Transplantation
/ adverse effects
Humans
Immune Reconstitution
Immunity, Innate
Immunophenotyping
Male
Middle Aged
Receptors, Antigen, T-Cell, gamma-delta
/ metabolism
T-Lymphocyte Subsets
/ immunology
Transplantation Conditioning
Transplantation Immunology
Transplantation, Homologous
Young Adult
allogeneic stem cell transplantation
cell therapy
gamma delta (γδ) T cells
innate immunology
transplant immunology
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2019
2019
Historique:
received:
21
12
2018
accepted:
07
08
2019
entrez:
12
9
2019
pubmed:
12
9
2019
medline:
2
10
2020
Statut:
epublish
Résumé
T-cell receptor (TCR) γδ cells are perceived as innate-like effector cells with the possibility of mediating graft-vs. -tumor (GVT) without causing graft-vs.-host disease (GVHD) in the setting of hematopoietic allogeneic stem cell transplantation (HSCT). We conducted a prospective study to assess the clinical impact of TCR γδ cell immune reconstitution on overall survival, relapse-free-survival, relapse and GVHD. The impact of CD3, CD4, and CD8 T cells together with NK cells including subtypes were analyzed in parallel. A total of 108 patients with hematological malignancies transplanted with HLA-matched, T cell replete stem cell grafts were included for analyses of absolute concentrations of CD3, CD4, and CD8 positive T cells and NK cells together with a multi-color flow cytometry panel with staining for TCRαβ, TCRγδ, Vδ1, Vδ2, CD3, CD4, CD8, HLA-DR, CD196, CD45RO, CD45RA, CD16, CD56, CD337, and CD314 at 28, 56, 91, 180, and 365 days after transplantation. Immune reconstitution data including subsets and differentiation markers of T and NK cells during the first year after transplantation was provided. Patients with TCR γδ cell concentrations above the median value of 21 (0-416) × 10
Identifiants
pubmed: 31507601
doi: 10.3389/fimmu.2019.01997
pmc: PMC6714591
doi:
Substances chimiques
Receptors, Antigen, T-Cell, gamma-delta
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1997Références
Science. 1999 Jul 30;285(5428):727-9
pubmed: 10426993
Bone Marrow Transplant. 2001 Mar;27(6):601-6
pubmed: 11319589
Trends Immunol. 2001 Nov;22(11):633-40
pubmed: 11698225
Bone Marrow Transplant. 1992 Sep;10(3):249-53
pubmed: 1422478
Science. 2005 Jul 8;309(5732):264-8
pubmed: 15933162
J Immunol. 2005 Aug 15;175(4):2144-51
pubmed: 16081780
Cancer Immunol Immunother. 2006 Sep;55(9):1072-80
pubmed: 16328383
N Engl J Med. 2006 Apr 27;354(17):1813-26
pubmed: 16641398
Immunol Rev. 2007 Feb;215:59-76
pubmed: 17291279
Bone Marrow Transplant. 2007 Jun;39(12):751-7
pubmed: 17450185
J Immunol. 2008 Aug 1;181(3):2227-37
pubmed: 18641363
Blood. 2008 Dec 1;112(12):4371-83
pubmed: 19029455
Blood. 2009 Jul 9;114(2):310-7
pubmed: 19436053
Blood. 2010 Mar 25;115(12):2407-11
pubmed: 20101024
Blood. 2010 Sep 23;116(12):2164-72
pubmed: 20576814
Blood. 2011 Aug 4;118(5):1402-12
pubmed: 21540462
Blood. 2011 Jul 7;118(1):50-9
pubmed: 21566093
Blood. 2011 Jul 28;118(4):992-1001
pubmed: 21633088
Trends Immunol. 2012 May;33(5):199-206
pubmed: 22364810
J Immunol. 2012 May 1;188(9):4701-8
pubmed: 22467661
Curr Opin Hematol. 2012 Jul;19(4):324-35
pubmed: 22517587
Cytotherapy. 2012 Oct;14(9):1110-8
pubmed: 22800570
Br J Haematol. 2013 Jan;160(2):123-32
pubmed: 23061882
Cell Mol Immunol. 2013 Jan;10(1):21-9
pubmed: 23085947
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Oncoimmunology. 2012 Dec 1;1(9):1652-1654
pubmed: 23264926
Leukemia. 2013 Jun;27(6):1328-38
pubmed: 23277330
Nat Rev Immunol. 2013 Feb;13(2):88-100
pubmed: 23348415
Nat Immunol. 2013 Sep;14(9):908-16
pubmed: 23872678
Blood. 2013 Sep 12;122(11):1863-72
pubmed: 23878143
J Leukoc Biol. 2013 Dec;94(6):1123-39
pubmed: 24108703
Leukemia. 2014 Jun;28(6):1181-90
pubmed: 24345790
Blood. 2014 Jun 5;123(23):3664-71
pubmed: 24744269
Biol Blood Marrow Transplant. 2015 Jan;21(1):130-6
pubmed: 25445640
Blood. 2015 Apr 9;125(15):2349-58
pubmed: 25612623
Scand J Immunol. 2015 Jun;81(6):459-68
pubmed: 25753378
Cell Mol Immunol. 2015 Nov;12(6):656-68
pubmed: 25864915
J Clin Invest. 2015 Jul 1;125(7):2677-89
pubmed: 26053664
Blood. 2016 May 19;127(20):2427-38
pubmed: 26884374
Bone Marrow Transplant. 2016 Jun;51(6):786-92
pubmed: 26901709
Front Immunol. 2016 Apr 15;7:144
pubmed: 27148263
Front Immunol. 2016 Nov 17;7:507
pubmed: 27909435
Nat Immunol. 2017 Apr;18(4):393-401
pubmed: 28218745
Oncoimmunology. 2016 Sep 27;6(2):e1216291
pubmed: 28344861
Front Immunol. 2017 Apr 25;8:465
pubmed: 28487696
Mol Ther. 2018 Feb 7;26(2):354-365
pubmed: 29310916
Blood. 2018 Mar 8;131(10):1063-1072
pubmed: 29358176
Curr Stem Cell Rep. 2017 Dec;3(4):301-311
pubmed: 29399441
Biol Blood Marrow Transplant. 2018 Jun;24(6):1152-1162
pubmed: 29505821
Bone Marrow Transplant. 2018 Jun;53(6):766-769
pubmed: 29515253
Bone Marrow Transplant. 2018 Nov;53(11):1450-1456
pubmed: 29662245
Front Immunol. 2018 May 07;9:984
pubmed: 29867961
Front Immunol. 2018 Jun 26;9:1409
pubmed: 29997614
Transplantation. 1974 Oct;18(4):295-304
pubmed: 4153799
Bone Marrow Transplant. 1995 Jun;15(6):825-8
pubmed: 7581076
Bone Marrow Transplant. 1994 Nov;14(5):741-6
pubmed: 7889006
Bone Marrow Transplant. 1996 Feb;17(2):243-7
pubmed: 8640174